Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06645704 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
A Phase 1 study, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06645704 is a Phase 1 study that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT06645704, a Phase 1 study, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is being conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\]-EP262 in healthy male participants.
Interventions
- DRUG EP262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2024-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06645704
The ClinicalTrials.gov registry entry for NCT06645704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Escient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EP262 is the first listed.
NCT06645704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06645704 about?
NCT06645704 is a clinical study titled "An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration". This study is being conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\]-EP262 in healthy male participants.
What is the current status of trial NCT06645704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-01. Estimated completion is 2024-12-10.
What interventions are being tested in trial NCT06645704?
The interventions under investigation include: EP262 (DRUG).
Who is sponsoring clinical trial NCT06645704?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.